Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):304-311. doi: 10.1007/s00259-023-06424-9. Epub 2023 Sep 12.
Unspecific bone uptake is one of the main limitations of PET imaging with some PSMA-targeting radiopharmaceuticals, especially with [F]PSMA-1007. We explored the potential association between osteoporosis and the occurrence of unspecific [F]PSMA-1007 bone uptake investigating markers which might correlate with bone mineral density.
We retrospectively analyzed treatment-naïve patients with a confirmed diagnosis of prostate adenocarcinoma who underwent staging [F]PSMA-1007 positron emission tomography (PET). Qualitative image analysis was performed independently by three experienced nuclear medicine physicians. Patients were divided in two groups according to the presence/absence of unspecific bone uptake. Clinical information, blood count parameters (assessed within 3 months to the PET scan), body mass index (BMI), and bone density as estimated by computed tomography were collected. The Kruskal-Wallis and t-test were used to compare parameters.
We analyzed 77 patients: 29 of them (38%) had unspecific bone uptake at [F]PSMA-1007 PET, most commonly in the pelvic bones (69%) and ribs (62%). We did not find any significant difference in clinical parameters in the two groups. In patients with unspecific bone uptake, white blood cell, and neutrophil counts were significantly higher; in the same group, we observed lower values of BMI and bone density, although not statistically different.
We observed unspecific bone uptake on [F]PSMA-1007 PET in more than 1/3 of patients. In this exploratory analysis, we found a significant correlation between blood count parameters and unspecific [F]PSMA-1007 bone uptake. We may speculate that [F]PSMA-1007 unspecific bone uptake could be associated with osteoporosis. This hypothesis needs to be further investigated in larger populations and exploring more specific markers of osteoporosis.
一些 PSMA 靶向放射性药物,尤其是 [F]PSMA-1007,其 PET 成像存在非特异性骨摄取,这是其主要局限性之一。我们通过研究可能与骨密度相关的标志物,探索骨质疏松症与非特异性 [F]PSMA-1007 骨摄取发生之间的潜在关联。
我们回顾性分析了接受分期 [F]PSMA-1007 正电子发射断层扫描(PET)的确诊前列腺腺癌的初治患者。由三位经验丰富的核医学医师独立进行定性图像分析。根据是否存在非特异性骨摄取,将患者分为两组。收集了临床信息、血液计数参数(在 PET 扫描前 3 个月内评估)、体重指数(BMI)和计算机断层扫描估计的骨密度。使用 Kruskal-Wallis 和 t 检验比较参数。
我们分析了 77 例患者:29 例(38%)在 [F]PSMA-1007 PET 中出现非特异性骨摄取,最常见于骨盆骨(69%)和肋骨(62%)。两组患者的临床参数无显著差异。在有非特异性骨摄取的患者中,白细胞和中性粒细胞计数显著较高;在同一组中,我们观察到 BMI 和骨密度值较低,但无统计学差异。
我们在超过 1/3 的患者中观察到 [F]PSMA-1007 PET 上的非特异性骨摄取。在这项探索性分析中,我们发现血液计数参数与非特异性 [F]PSMA-1007 骨摄取之间存在显著相关性。我们可以推测 [F]PSMA-1007 的非特异性骨摄取可能与骨质疏松症有关。这一假设需要在更大的人群中进一步研究,并探索更具体的骨质疏松症标志物。